Haemonetics (HAE) Liabilities and Shareholders Equity (2016 - 2025)
Haemonetics has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $2.5 billion for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $2.5 billion for Q4 2025, down 1.6% from a year ago — trailing twelve months through Dec 2025 was $9.8 billion (up 0.54% YoY), and the annual figure for FY2025 was $2.5 billion, up 11.63%.
- Liabilities and Shareholders Equity for Q4 2025 was $2.5 billion at Haemonetics, up from $2.4 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for HAE hit a ceiling of $2.5 billion in Q2 2024 and a floor of $1.8 billion in Q3 2021.
- Median Liabilities and Shareholders Equity over the past 5 years was $2.0 billion (2023), compared with a mean of $2.1 billion.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 43.63% in 2021 and later fell 3.29% in 2025.
- Haemonetics' Liabilities and Shareholders Equity stood at $1.8 billion in 2021, then grew by 4.25% to $1.9 billion in 2022, then rose by 17.16% to $2.2 billion in 2023, then grew by 15.04% to $2.5 billion in 2024, then fell by 1.6% to $2.5 billion in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $2.5 billion (Q4 2025), $2.4 billion (Q3 2025), and $2.5 billion (Q2 2025) per Business Quant data.